Patents by Inventor Janet Louise Lines

Janet Louise Lines has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VISTA Antagonist and Methods of Use
    Publication number: 20240158507
    Abstract: The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.
    Type: Application
    Filed: November 20, 2023
    Publication date: May 16, 2024
    Inventors: Randolph J. Noelle, Li Wang, Thomas Broughton, Lorenzo F. Sempere, Janet Louise Lines
  • VISTA Antagonist and Methods of Use
    Publication number: 20210253708
    Abstract: The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a-1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.
    Type: Application
    Filed: November 9, 2020
    Publication date: August 19, 2021
    Inventors: Randolph J. Noelle, Li Wang, Thomas Broughton, Lorenzo F. Sempere, Janet Louise Lines
  • VISTA Agonist and Methods of Use
    Publication number: 20180237525
    Abstract: The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.
    Type: Application
    Filed: April 14, 2015
    Publication date: August 23, 2018
    Inventors: Randolph J. Noelle, Li Wang, Thomas Broughton, Lorenzo F. Sempere, Janet Louise Lines
  • VISTA Antagonist and Methods of Use
    Publication number: 20160083472
    Abstract: The present invention is directed to synergic or additive therapies comprising the administration of a VISTA antagonist and a PD-1, PD-L1 or POD-L3 antagonist; or the combination of a VISTA agonist and a -1, PD-L1 or POD-L3 agonist which combinations respectively elicit an additive or synergistic effect at promoting T cell immunity or inhibiting T cell immunity, i.e., CD4, CD8 or Th1 immunity. The agonists and antagonists may be in the same or separate compositions and may be administered together or separately administered in either order.
    Type: Application
    Filed: April 14, 2015
    Publication date: March 24, 2016
    Inventors: Randolph J. Noelle, Li Wang, Thomas Broughton, Lorenzo F. Sempere, Janet Louise Lines